biotech startups: Why are buyers shying away from biotech startups?
Although that was a constructive growth, the whole valuation of the 325 startups that C-CAMP backs is barely Rs 6,000 crore, or lower than $1 billion at present alternate charges. Of those, practically 100 startups are lower than two years outdated. (Illustration: Rahul Awasthi/ETtech)
Synopsis
Buyers have largely been risk-averse in the case of deep-funding biotech startups which have the potential to show into billion-dollar entities. Why are they shying away from this area?
Are Indian biotechnology startups undervalued?
There are about 5,000 biotech firms within the nation, of which greater than 4,000 are startups. Whereas Bengaluru-based Biocon Biologics and Syngene are valued at $1 billion or extra – recognized in startup trade parlance as unicorns – different biotech startups have but to get there.
Lately, seven deep-tech startups on the Centre for Mobile and Molecular Platforms (C-CAMP) in Bengaluru raised about $70
- FONT SIZE
AbcSmall
AbcMedium
AbcGiant
Why ?
Unique Financial Occasions Tales, Editorials & Professional opinion throughout 20+ sectors
Inventory evaluation. Market Analysis. Business Traits on 4000+ Shares
Clear expertise with
Minimal Advertisements
Remark & Interact with ET Prime neighborhood
Unique invitations to Digital Occasions with Business Leaders
A trusted workforce of Journalists & Analysts who can finest filter sign from noise
